Work

Supplemental Table 2 from A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

Year: 2023

Type: supplementary-materials

Abstract: Supplemental Table 2. Dose escalation PK parameters for ARRY-614

DOI: 10.1158/1078-0432.22461650

Authors: Guillermo Garcia-Manero, Hanna J. Khoury, Elias Jabbour, Jeffrey Lancet, Shannon L. Winski, LouAnn Cable, Selena Rush, Lara Maloney, Grant Hogeland, Mieke Ptaszynski, Monica Cabrero Calvo, Zach Bohannan, Alan List, Hagop Kantarjian, Rami Komrokji

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361885452

Cites:

Cited by:

Related to: 10